Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma

Objective To review the current evidence on the use of immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs) in the treatment of multiple myeloma (MM). Data Sources Journal articles, research reports, state of the science papers, and clinical guidelines. Conclusion There has been a tremendous increase of new agents to treat multiple myeloma in the last 15 years. The IMiDs and PIs remain essential components of many anti-myeloma regimens. Implications for Nursing Practice With these advances in the therapeutic landscape, knowledge of these drugs, side effects and nursing implications are essential to improve outcomes. Patient education is also of vital importance in achieving optimal responses to treatment.